Delights and let-downs in the management of tumor necrosis factor receptor-associated periodic syndrome: the canakinumab experience in a patient with a high-penetrance T50M TNFRSF1A variant

Luca Cantarini, Giuseppe Lopalco, Antonio Vitale, Francesco Caso, Giovanni Lapadula, Florenzo Iannone, Mauro Galeazzi, Donato Rigante

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)

Abstract

The anti-IL1 drug canakinumab has been administered in a patient with a high-penetrance T50M TNFRSF1A variant: this experience has been discussed in this manuscript.
Original languageEnglish
Pages (from-to)473-475
Number of pages3
JournalInternational Journal of Rheumatic Diseases
Volume18
DOIs
Publication statusPublished - 2015

Keywords

  • Autoinflammation

Fingerprint

Dive into the research topics of 'Delights and let-downs in the management of tumor necrosis factor receptor-associated periodic syndrome: the canakinumab experience in a patient with a high-penetrance T50M TNFRSF1A variant'. Together they form a unique fingerprint.

Cite this